HER2 and gastric cancer. Recommendations for clinical practice in 2011;HER2 et cancer gastrique. Recommandations pour la pratique clinique en 2011

Annales de Pathologie

Volumn 31, Issue 2, 2011, Pages 78-87

  Penault Llorca, Frédérique ^a,b   Chenard, Marie Pierre ^c   Bouché, Olivier ^d   Émile, Jean François ^e   Bibeau, Frédéric ^f   Metges, Jean Philippe ^g   André, Thierry ^h   Monges, Geneviève ⁱ  

^a CENTRE JEAN PERRIN   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d SERVICE DE DERMATOLOGIE   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

^f CENTRE VAL D AURELLE   (France)

^g CHU MORVAN   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ INSTITUT PAOLI CALMETTES   (France)

Author keywords

Gastric cancer; Guidelines; HER2; Immunohistochemistry; In situ hybridization; Trastuzumab

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; TRASTUZUMAB;

ACCURACY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL PROTOCOL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; METASTASIS; PATIENT SELECTION; PRACTICE GUIDELINE; SILVER IN SITU HYBRIDIZATION; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; STOMACH CANCER;

ADENOCARCINOMA; HUMANS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 79956069238     PISSN: 02426498     EISSN: 02426498     Source Type: Journal    
DOI: 10.1016/j.annpat.2011.03.001     Document Type: Article

References (31)

1. Ross J.S., Slodkowska E.A., Symmans W.F., et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368.
2. Park D.I., Yun J.W., Park J.H., et al. Her2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006, 51:1371-1379.
3. Yano T., Doi T., Ohtsu A., et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006, 15:65-71.
4. Hofmann M., Stoss O., Shi D., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52:797-805.
5. Marx A.H., Tharun L., Muth J., et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009, 40:769-777.
6. Zhang X.L., Yang Y.S., Xu D.P., et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009, 33:2112-2118.
7. Nakajima M., Sawada H., Yamada Y., et al. The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer 1999, 85:1894-1902.
8. Allgayer H., Babic R., Gruetzner K.U., Tarabichi A., Schildberg F.W., Heiss M.M. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumorassociated protease systems. J Clin Oncol 2000, 18:2201-2209.
9. García I., Vizoso F., Martín A., Sanz L., Abdel-Lah O., Raigoso P., et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003, 10:234-241.
10. Tanner M., Hollmén M., Junttila T.T., et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005, 16:273-278.
11. Matsui Y., Inomata M., Tojigamori M., et al. Suppression of tumor growth in human gastric cancer with HER2 over-expression by an anti-HER2 antibody in a murine model. Int J Oncol 2005, 27:681-685.
12. Fujimoto-Ouchi K., Sekiguchi F., Yasuno H., et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007, 59:795-805.
13. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
14. Herceptin EU SmPC. Available at: 2010 [Accessed November 12, 2010]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf.
15. Penault-Llorca F., Vincent-Salomon A., Bellocq J.P., Mathieu M.C., Mac Grogan, Treilleux I., et al. Mise à jour des recommandations du GEFPICS pour l'évaluation du statut HER2 dans les cancers du sein en France. Ann Pathol 2010, 30:357-373. [Epub 2010 Oct 16].
16. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology; College of American Pathologists, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
17. Srinivasan M., Sedmak D., Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Path 2002, 161:1961-1971.
18. Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., Schnitt S.J. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999, 17:1983-1987.
19. DiVito K.A., Charette L.A., Rimm D.L., Camp R.L. Long-term preservation of antigenicity on tissue microarrays. Lab Invest 2004, 84:1071-1078.
20. Atkins D., Reiffen K.A., Tegtmeier C.L., Winther H., Bonato M.S., Störkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004, 52:893-901.
21. Penault-Llorca F., Bilous M., Dowsett M., Hanna W., Osamura R.Y., Rüschoff J., et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol 2009, 132:539-548.
22. Cayre A., Mishellany F., Lagarde N., Penault-Llorca F. Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification. Breast Cancer Res 2007, 9(5):R64.
23. Recommandations de bonnes pratiques en ACP: (available from http://www.afaqap.org/ecrire/upload/201001181206340.RBPACP%2520v2_2009-web.pdf.
24. Rüschoff J., Dietel M., Baretton G., Arbogast S., Walch A., Monges G., et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010, 457:299-307. [Epub 2010 Jul 28].
25. Lauren T. The two histologic main type of gastric carcinoma. Acta Pathol Microbiol Scand 1965, 64:34.
26. Bang Y.J., Chung H., Xu J.M., Lordick F., Sawaki A., Lipatov O., et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009, 27:15s. [suppl; abstr 4556].
27. Powell WC, Zielinski D, Ranger-Moore J, Nagelmeier I, Stoss O, Ruschoff J, et al. Determining the HER2 status in gastric cancer: a method comparison study of two patient cohorts. ASCO GI 2010 [abstr 17].
28. Recommandations de la Société française d'endoscopie digestive. De la pratique des biopsies œsogastroduodénales (septembre 2005) http://www.sfed.org/documents_sfed/files/recommandations/Biopsie_oesogastroduodenale.pdf.
29. Thésaurus National de cancérologie digestive http://www.snfge.org/data/ModuleDocument/publication/5/pdf/TNCD-chapitre-1288.pdf.
30. Rüschoff J., Nagelmeier I., Baretton G., et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer?. Der Pathologe 2010, 31:208-217.
31. Park Y.S., Jang S.J., Park H.J., Ryu M.H., Ryoo B.Y., Yook J.H., et al. HER2 overexpression and gene amplification in gastric cancers: which scoring system should we use?. Ann Oncol 2010, 21(Suppl. 8):P822.